You are here:
Archived: aliskiren (Rasilez)
Advice
Following a full submission
aliskiren (Rasilez) is not recommended for use within NHS Scotland for the treatment of essential hypertension.
Aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, though its effects on mortality and long-term morbidity are currently unknown.
The manufacturer did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC for the position sought.
Drug Details
| Drug Name: | aliskiren (Rasilez) |
|---|---|
| SMC Drug ID: | 462/08 |
| Manufacturer: | Novartis Pharmaceuticals UK Ltd |
| Indication: | Essential hypertension |
| BNF Category: | |
| Sub Category: | 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs |
| Submission Type: | Full submission |
| Status: | Not Recommended |
| Date Advice Published: | 12 January 2009 |
Current Advice
| aliskiren (Rasilez)_resub | Resubmission | 8 February 2010 |
Archived Advice
| aliskiren (Rasilez)_nonsub | Non submission | 12 May 2008 |